Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegloticase in Refractory Chronic Gout
NCT00325195Phase 3Completed
- Sponsor
- Savient Pharmaceuticals
- Start
- May 2006
- Primary completion
- Oct 2007
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of pegloticase in gout (3 arms), sponsored by Savient Pharmaceuticals. Primary endpoint: Plasma Uric Acid Responder at 6 months. Started May 2006; status: completed.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT00325195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00325195.